Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://wkd.com.pl
Are you over 18 and want to see adult content?
A complete backup of https://shapladoelsangsad.com
Are you over 18 and want to see adult content?
A complete backup of https://bethelrichmond.org
Are you over 18 and want to see adult content?
A complete backup of https://ics.org.uk
Are you over 18 and want to see adult content?
A complete backup of https://equitynet.com
Are you over 18 and want to see adult content?
A complete backup of https://umarkets.net
Are you over 18 and want to see adult content?
A complete backup of https://jbweld.com
Are you over 18 and want to see adult content?
A complete backup of https://oktodev.com
Are you over 18 and want to see adult content?
A complete backup of https://educenter.id
Are you over 18 and want to see adult content?
A complete backup of https://gordon.edu
Are you over 18 and want to see adult content?
A complete backup of https://nimbuzz.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of ortopediacanina.com
Are you over 18 and want to see adult content?
A complete backup of jayadeeppulikallu.wordpress.com
Are you over 18 and want to see adult content?
A complete backup of panoramagique.com
Are you over 18 and want to see adult content?
A complete backup of varunmultimedia.org
Are you over 18 and want to see adult content?
Text
vaccination.
COVID-19 VACCINATION IN AUTOIMMUNE DISEASES: PATIENT This feature is part of the Autoimmune Disease Awareness Month series. The Centers for Disease Control and Prevention (CDC) recommends that individuals with autoimmune diseases and those with weakened immune systems receive the COVID-19 vaccines; however, no solid data are currently available regarding their safety specifically in populations with autoimmune conditions. 1 On HERPES ZOSTER REACTIVATION AFTER COVID-19 VACCINATION A potential association between vaccination against COVID-19 and herpes zoster (HZ) reactivation in patients with stable autoimmune inflammatory rheumatic diseases (AIIRD) was examined, and the results of the report were published in Rheumatology.Study authors noted that among patients with AIIRD who received the Pfizer-BioNTech COVID-19 vaccine, the prevalence of herpes zoster was ACR RELEASES COVID-19 VACCINE CLINICAL GUIDANCE FOR The American College of Rheumatology (ACR) coronavirus disease 2019 (COVID-19) Vaccine Clinical Guidance Task Force has issued consensus-based recommendations for the use of COVID-19 vaccines in patients with rheumatic and musculoskeletal diseases (RMDs). COUNSELING IMMUNOCOMPROMISED PATIENTS ABOUT THE JOHNSONAUTHOR: MEGHNARAO
In February 2021, the American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Task Force developed recommendations for providers regarding the use of the COVID-19 vaccine and the management of patients with rheumatic and musculoskeletal diseases (RMDs) during vaccination. 1 This “living” document was updated in March 2021 to reflect evolving evidence and EFFECT OF RITUXIMAB TIMING ON COVID-19-RELATED DEATH IN Timing of rituximab treatment and immunoglobulin (Ig) levels may be associated with an increased risk for COVID)-19-related death in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), according to a research letter published in Rheumatology.. Several studies have suggested that rituximab, an anti-CD20 therapy approved for remission induction of AAV, may be RHEUMATOLOGY ADVISORRHEUMATOID ARTHRITISSPONDYLOARTHRITISOSTEOARTHRITISLUPUSGOUTNEWS Assistant professor in medicine and pediatrics and study author Rebecca Sadun, MD, discusses current health care transition practices and beliefs among CARRA rheumatology providers and provides insight into the positive impact of improvements to the transition process from pediatric to adult rheumatology care. ACR UPDATES COVID-19 VACCINE GUIDANCE FOR MANAGINGAUTHOR: MEGHNA RAO In February 2021, the American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Task Force released a summary of consensus-based recommendations for the management of patients with rheumatic and musculoskeletal diseases (RMDs) with regard to COVID-19vaccination.
COVID-19 VACCINATION IN AUTOIMMUNE DISEASES: PATIENT This feature is part of the Autoimmune Disease Awareness Month series. The Centers for Disease Control and Prevention (CDC) recommends that individuals with autoimmune diseases and those with weakened immune systems receive the COVID-19 vaccines; however, no solid data are currently available regarding their safety specifically in populations with autoimmune conditions. 1 On HERPES ZOSTER REACTIVATION AFTER COVID-19 VACCINATION A potential association between vaccination against COVID-19 and herpes zoster (HZ) reactivation in patients with stable autoimmune inflammatory rheumatic diseases (AIIRD) was examined, and the results of the report were published in Rheumatology.Study authors noted that among patients with AIIRD who received the Pfizer-BioNTech COVID-19 vaccine, the prevalence of herpes zoster was ACR RELEASES COVID-19 VACCINE CLINICAL GUIDANCE FOR The American College of Rheumatology (ACR) coronavirus disease 2019 (COVID-19) Vaccine Clinical Guidance Task Force has issued consensus-based recommendations for the use of COVID-19 vaccines in patients with rheumatic and musculoskeletal diseases (RMDs). COUNSELING IMMUNOCOMPROMISED PATIENTS ABOUT THE JOHNSONAUTHOR: MEGHNARAO
In February 2021, the American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Task Force developed recommendations for providers regarding the use of the COVID-19 vaccine and the management of patients with rheumatic and musculoskeletal diseases (RMDs) during vaccination. 1 This “living” document was updated in March 2021 to reflect evolving evidence and EFFECT OF RITUXIMAB TIMING ON COVID-19-RELATED DEATH IN Timing of rituximab treatment and immunoglobulin (Ig) levels may be associated with an increased risk for COVID)-19-related death in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), according to a research letter published in Rheumatology.. Several studies have suggested that rituximab, an anti-CD20 therapy approved for remission induction of AAV, may be COVID-19 AND INCIDENT SYSTEMIC RHEUMATIC DISEASE Study authors determined the potential association between COVID-19 and subsequent diagnosis with a systemic rheumatic disease, in a correspondence paper published in Lancet Rheumatology.Using a case series study, the authors noted that a SAFETY AND EFFICACY OF SARS-COV-2 MRNA VACCINES IN The mRNA vaccines against SARS-CoV-2 were found to be immunogenic, without considerable side effects or the induction of disease flares in patients with chronic inflammatory diseases (CIDs), according to study results published in Annals of the Rheumatic Diseases.. Limited data are available on the efficacy and safety of mRNA vaccines in patients receiving immunosuppressive MAVRILIMUMAB REDUCES PROGRESSION TO MECHANICAL VENTILATION In an ongoing, global, randomized, double-blind, placebo-controlled phase 2/3 trial, researchers aimed to determine the safety and efficacy of mavrilimumab in adults hospitalized with severe COVID-19 pneumonia and systemic hyperinflammation.. In phase 2 of the trial, participants requiring supplemental oxygen therapy without mechanical ventilation were assigned to cohort 1 and GEOGRAPHIC AND TEMPORAL VARIATIONS OBSERVED WITH The use of repurposed and adjuvant drugs during the COVID-19 pandemic varied geographically and temporally, based on the emergence of safety and efficacy data, according to findings from a multinational cohort study published in BMJ.. The urgency during the COVID-19 pandemic led to the rapid use of repurposed drugs and adjunctive treatments, without evidence of their effectiveness. ANAKINRA REDUCES NEED FOR MECHANICAL VENTILATION AND Treatment with anakinra reduces the need for invasive mechanical ventilation and mortality risk in hospitalized nonintubated patients with COVID-19, according to a meta-analysis published in Rheumatology.. Previous studies have suggested that interleukin (IL)-1 receptor antagonist anakinra, used for the treatment of autoinflammatory disorders, may improve hyperinflammatory symptoms in DECLINE IN EXCESS HEART FAILURE RISK OBSERVED AMONG Research has indicated a 2-fold excess risk for heart failure in patients with rheumatoid arthritis vs the general population. Credit: Getty Images The following article is a part of conference coverage from the European Alliance of Associations for REVIEW: COVID-19 VASCULITIS OR NOVEL VASCULITIS MIMIC Mc Gonagle and colleagues also explored whether involvement of the brain in COVID-19 stemmed from a vasculitis mimic or viral infection. Severe small arteriolar and venular thromboses have been found in the kidneys, liver, and spleen of patients with severe COVID-19, and it remains unclear whether these are mediated by a vasculitis mimic. 2. PSORIASIS AND PSORIATIC ARTHRITIS: PROVIDING BIDIRECTIONAL 1 day ago · Alexis Ogdie, MD, is an associate professor of medicine and epidemiology, deputy director of the Penn Center for Clinical Epidemiology, and director of the Penn Psoriatic Arthritis and Spondyloarthritis Program at the Perelman School of Medicine, University of Pennsylvania. Dr Ogdie’s research program is focused PsA, an inflammatory arthritis that affects up to 30% of patients withTHYROID SYNDROMES
Does this patient have thyroid syndrome? Thyroid disease can be accompanied by a variety of musculoskeletal manifestations ranging from early growth defects during infancy to adult manifestations including myalgias, arthralgias, myopathy, acropachy and frank arthritis. Musculoskeletal manifestations are most pronounced in extreme states of thyroid dysfunction. A thorough history is essential 3 CONDITIONS THAT LOOKS LIKE LYME DISEASE Borrelia miyamotoi (B miyamotoi) disease is an emerging infectious disease spread by deer ticks.First discovered by Japanese scientists in 1995, B miyamotoi disease can be found in all areas of the United States where Lyme disease is endemic. 1 The first human cases of B miyamotoi infection were found in Russia in 2011, when researchers identified 46 patients who had presented with the RHEUMATOLOGY ADVISORRHEUMATOID ARTHRITISSPONDYLOARTHRITISOSTEOARTHRITISLUPUSGOUTNEWS Assistant professor in medicine and pediatrics and study author Rebecca Sadun, MD, discusses current health care transition practices and beliefs among CARRA rheumatology providers and provides insight into the positive impact of improvements to the transition process from pediatric to adult rheumatology care. ACR UPDATES COVID-19 VACCINE GUIDANCE FOR MANAGING In February 2021, the American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Task Force released a summary of consensus-based recommendations for the management of patients with rheumatic and musculoskeletal diseases (RMDs) with regard to COVID-19vaccination.
HERPES ZOSTER REACTIVATION AFTER COVID-19 VACCINATION A potential association between vaccination against COVID-19 and herpes zoster (HZ) reactivation in patients with stable autoimmune inflammatory rheumatic diseases (AIIRD) was examined, and the results of the report were published in Rheumatology.Study authors noted that among patients with AIIRD who received the Pfizer-BioNTech COVID-19 vaccine, the prevalence of herpes zoster was COVID-19 VACCINATION IN AUTOIMMUNE DISEASES: PATIENT This feature is part of the Autoimmune Disease Awareness Month series. The Centers for Disease Control and Prevention (CDC) recommends that individuals with autoimmune diseases and those with weakened immune systems receive the COVID-19 vaccines; however, no solid data are currently available regarding their safety specifically in populations with autoimmune conditions. 1 On A CLOSER LOOK AT THE RISK FOR SEVERE OUTCOMES WITH LOW The risk for severe outcomes with low-dose glucocorticoids in patients with rheumatoid arthritis (RA) increases over time, particularly after 6 years and up to 10 years of treatment, study findings published in Rheumatology suggest.. This study analyzed 10-year outcomes data obtained from the prospective, observational ESPOIR cohort, which included patients with early arthritis (mean age, 47.5 ACR RELEASES COVID-19 VACCINE CLINICAL GUIDANCE FOR The American College of Rheumatology (ACR) coronavirus disease 2019 (COVID-19) Vaccine Clinical Guidance Task Force has issued consensus-based recommendations for the use of COVID-19 vaccines in patients with rheumatic and musculoskeletal diseases (RMDs). COUNSELING IMMUNOCOMPROMISED PATIENTS ABOUT THE JOHNSONAUTHOR: MEGHNARAO
In February 2021, the American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Task Force developed recommendations for providers regarding the use of the COVID-19 vaccine and the management of patients with rheumatic and musculoskeletal diseases (RMDs) during vaccination. 1 This “living” document was updated in March 2021 to reflect evolving evidence and EFFECT OF RITUXIMAB TIMING ON COVID-19-RELATED DEATH IN Timing of rituximab treatment and immunoglobulin (Ig) levels may be associated with an increased risk for COVID)-19-related death in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), according to a research letter published in Rheumatology.. Several studies have suggested that rituximab, an anti-CD20 therapy approved for remission induction of AAV, may be DO VACCINES INCREASE RISK FOR GOUT FLARES? Vaccines May Increase Risk for Gout Flares, But Benefits of Vaccination Outweigh Risks. Tom Greenhalgh. Patients with gout were found to be twice as likely to experience a flare in the days following vaccination compared with periods when vaccination was not administered. Patients with gout were found to be twice as likely toexperience a flare
3 CONDITIONS THAT LOOKS LIKE LYME DISEASE Borrelia miyamotoi (B miyamotoi) disease is an emerging infectious disease spread by deer ticks.First discovered by Japanese scientists in 1995, B miyamotoi disease can be found in all areas of the United States where Lyme disease is endemic. 1 The first human cases of B miyamotoi infection were found in Russia in 2011, when researchers identified 46 patients who had presented with the RHEUMATOLOGY ADVISORRHEUMATOID ARTHRITISSPONDYLOARTHRITISOSTEOARTHRITISLUPUSGOUTNEWS Assistant professor in medicine and pediatrics and study author Rebecca Sadun, MD, discusses current health care transition practices and beliefs among CARRA rheumatology providers and provides insight into the positive impact of improvements to the transition process from pediatric to adult rheumatology care. ACR UPDATES COVID-19 VACCINE GUIDANCE FOR MANAGING In February 2021, the American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Task Force released a summary of consensus-based recommendations for the management of patients with rheumatic and musculoskeletal diseases (RMDs) with regard to COVID-19vaccination.
HERPES ZOSTER REACTIVATION AFTER COVID-19 VACCINATION A potential association between vaccination against COVID-19 and herpes zoster (HZ) reactivation in patients with stable autoimmune inflammatory rheumatic diseases (AIIRD) was examined, and the results of the report were published in Rheumatology.Study authors noted that among patients with AIIRD who received the Pfizer-BioNTech COVID-19 vaccine, the prevalence of herpes zoster was COVID-19 VACCINATION IN AUTOIMMUNE DISEASES: PATIENT This feature is part of the Autoimmune Disease Awareness Month series. The Centers for Disease Control and Prevention (CDC) recommends that individuals with autoimmune diseases and those with weakened immune systems receive the COVID-19 vaccines; however, no solid data are currently available regarding their safety specifically in populations with autoimmune conditions. 1 On A CLOSER LOOK AT THE RISK FOR SEVERE OUTCOMES WITH LOW The risk for severe outcomes with low-dose glucocorticoids in patients with rheumatoid arthritis (RA) increases over time, particularly after 6 years and up to 10 years of treatment, study findings published in Rheumatology suggest.. This study analyzed 10-year outcomes data obtained from the prospective, observational ESPOIR cohort, which included patients with early arthritis (mean age, 47.5 ACR RELEASES COVID-19 VACCINE CLINICAL GUIDANCE FOR The American College of Rheumatology (ACR) coronavirus disease 2019 (COVID-19) Vaccine Clinical Guidance Task Force has issued consensus-based recommendations for the use of COVID-19 vaccines in patients with rheumatic and musculoskeletal diseases (RMDs). COUNSELING IMMUNOCOMPROMISED PATIENTS ABOUT THE JOHNSONAUTHOR: MEGHNARAO
In February 2021, the American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Task Force developed recommendations for providers regarding the use of the COVID-19 vaccine and the management of patients with rheumatic and musculoskeletal diseases (RMDs) during vaccination. 1 This “living” document was updated in March 2021 to reflect evolving evidence and EFFECT OF RITUXIMAB TIMING ON COVID-19-RELATED DEATH IN Timing of rituximab treatment and immunoglobulin (Ig) levels may be associated with an increased risk for COVID)-19-related death in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), according to a research letter published in Rheumatology.. Several studies have suggested that rituximab, an anti-CD20 therapy approved for remission induction of AAV, may be DO VACCINES INCREASE RISK FOR GOUT FLARES? Vaccines May Increase Risk for Gout Flares, But Benefits of Vaccination Outweigh Risks. Tom Greenhalgh. Patients with gout were found to be twice as likely to experience a flare in the days following vaccination compared with periods when vaccination was not administered. Patients with gout were found to be twice as likely toexperience a flare
3 CONDITIONS THAT LOOKS LIKE LYME DISEASE Borrelia miyamotoi (B miyamotoi) disease is an emerging infectious disease spread by deer ticks.First discovered by Japanese scientists in 1995, B miyamotoi disease can be found in all areas of the United States where Lyme disease is endemic. 1 The first human cases of B miyamotoi infection were found in Russia in 2011, when researchers identified 46 patients who had presented with the MAVRILIMUMAB REDUCES PROGRESSION TO MECHANICAL VENTILATION In an ongoing, global, randomized, double-blind, placebo-controlled phase 2/3 trial, researchers aimed to determine the safety and efficacy of mavrilimumab in adults hospitalized with severe COVID-19 pneumonia and systemic hyperinflammation.. In phase 2 of the trial, participants requiring supplemental oxygen therapy without mechanical ventilation were assigned to cohort 1 and DECLINE IN EXCESS HEART FAILURE RISK OBSERVED AMONG Research has indicated a 2-fold excess risk for heart failure in patients with rheumatoid arthritis vs the general population. Credit: Getty Images The following article is a part of conference coverage from the European Alliance of Associations for ANAKINRA REDUCES NEED FOR MECHANICAL VENTILATION AND Treatment with anakinra reduces the need for invasive mechanical ventilation and mortality risk in hospitalized nonintubated patients with COVID-19, according to a meta-analysis published in Rheumatology.. Previous studies have suggested that interleukin (IL)-1 receptor antagonist anakinra, used for the treatment of autoinflammatory disorders, may improve hyperinflammatory symptoms in PSORIASIS AND PSORIATIC ARTHRITIS: PROVIDING BIDIRECTIONAL Alexis Ogdie, MD, is an associate professor of medicine and epidemiology, deputy director of the Penn Center for Clinical Epidemiology, and director of the Penn Psoriatic Arthritis and Spondyloarthritis Program at the Perelman School of Medicine, University of Pennsylvania. Dr Ogdie’s research program is focused PsA, an inflammatory arthritis that affects up to 30% of patients with GEOGRAPHIC AND TEMPORAL VARIATIONS OBSERVED WITH The use of repurposed and adjuvant drugs during the COVID-19 pandemic varied geographically and temporally, based on the emergence of safety and efficacy data, according to findings from a multinational cohort study published in BMJ.. The urgency during the COVID-19 pandemic led to the rapid use of repurposed drugs and adjunctive treatments, without evidence of their effectiveness. MOVING TOWARD A MULTIDISCIPLINARY APPROACH IN PAIN 2 hours ago · Pain is a common overlapping factor between psoriasis and psoriatic arthritis (PsA). 1 According to a 2021 review by Kodumudi and Rajput, painful psoriasis and psoriatic arthropathy may be underreported in practice, resulting in substantial undertreatment of the pain. 1 Plaque psoriasis, with primary symptoms of itching and flaking skin lesions, affects an estimated 7.4% of the general THE CHALLENGES OF MANAGING COMORBIDITIES IN RHEUMATOID Further increases occurred within the year of diagnosis (8.7 disorders), followed by a decline in the 5 years after diagnosis (6.9 disorders). The top comorbidities in patients with RA compared with control participants were musculoskeletal, hematologic, and neurologic disorders. 3 Results of a 2019 study coauthored by Vanessa L. Kronzer, MD, an internal medicine resident at Mayo Clinic in SOMATIC UBA1 MUTATIONS CAUSAL FOR VEXAS IN PATIENTS WITH Mortality was significantly greater among patients with relapsing polychondritis with UBA1 mutations than those with relapsing polychondritis alone (P =.01). Credit: Getty Images The following article is a part of conference coverage from the European Alliance ofAssociations for
COLLEEN STINCHCOMBE, AUTHOR AT RHEUMATOLOGY ADVISOR 1 day ago · We speak to two doctors about life after hanging uptheir white coats
TNF INHIBITOR THERAPY IMPROVES BODY COMPOSITION, MUSCLE At 1 year after TNFi treatment, body composition changes corresponded with an improvement in handgrip strength and walk test at 6 months and 12 months. Credit: Getty Images Treatment with a tumor necrosis factor inhibitor (TNFi) for 1 year was associated with favorable changes intotal lean mass
RHEUMATOLOGY ADVISORRHEUMATOID ARTHRITISSPONDYLOARTHRITISOSTEOARTHRITISLUPUSGOUTNEWS Assistant professor in medicine and pediatrics and study author Rebecca Sadun, MD, discusses current health care transition practices and beliefs among CARRA rheumatology providers and provides insight into the positive impact of improvements to the transition process from pediatric to adult rheumatology care. ACR UPDATES COVID-19 VACCINE GUIDANCE FOR MANAGING In February 2021, the American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Task Force released a summary of consensus-based recommendations for the management of patients with rheumatic and musculoskeletal diseases (RMDs) with regard to COVID-19vaccination.
HERPES ZOSTER REACTIVATION AFTER COVID-19 VACCINATION A potential association between vaccination against COVID-19 and herpes zoster (HZ) reactivation in patients with stable autoimmune inflammatory rheumatic diseases (AIIRD) was examined, and the results of the report were published in Rheumatology.Study authors noted that among patients with AIIRD who received the Pfizer-BioNTech COVID-19 vaccine, the prevalence of herpes zoster was COVID-19 VACCINATION IN AUTOIMMUNE DISEASES: PATIENT This feature is part of the Autoimmune Disease Awareness Month series. The Centers for Disease Control and Prevention (CDC) recommends that individuals with autoimmune diseases and those with weakened immune systems receive the COVID-19 vaccines; however, no solid data are currently available regarding their safety specifically in populations with autoimmune conditions. 1 On COUNSELING IMMUNOCOMPROMISED PATIENTS ABOUT THE JOHNSONAUTHOR: MEGHNARAO
In February 2021, the American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Task Force developed recommendations for providers regarding the use of the COVID-19 vaccine and the management of patients with rheumatic and musculoskeletal diseases (RMDs) during vaccination. 1 This “living” document was updated in March 2021 to reflect evolving evidence and TREAT-TO-TARGET STRATEGY HELPS ELDERLY PATIENTS WITH In elderly patients with new-onset rheumatoid arthritis (RA), a treat-to-target (T2T) strategy using methotrexate (MTX) and biologic disease-modifying antirheumatic drugs (bDMARDs) was safe and effective, according to study results published in Rheumatology.. The recommended approach for treatment of patients with RA is based on levels of disease activity and additional patient factors. DO VACCINES INCREASE RISK FOR GOUT FLARES? Vaccines May Increase Risk for Gout Flares, But Benefits of Vaccination Outweigh Risks. Tom Greenhalgh. Patients with gout were found to be twice as likely to experience a flare in the days following vaccination compared with periods when vaccination was not administered. Patients with gout were found to be twice as likely toexperience a flare
RHEUMATOLOGY ADVISORRHEUMATOID ARTHRITISSPONDYLOARTHRITISOSTEOARTHRITISLUPUSGOUTNEWS Assistant professor in medicine and pediatrics and study author Rebecca Sadun, MD, discusses current health care transition practices and beliefs among CARRA rheumatology providers and provides insight into the positive impact of improvements to the transition process from pediatric to adult rheumatology care. ACR UPDATES COVID-19 VACCINE GUIDANCE FOR MANAGING In February 2021, the American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Task Force released a summary of consensus-based recommendations for the management of patients with rheumatic and musculoskeletal diseases (RMDs) with regard to COVID-19vaccination.
HERPES ZOSTER REACTIVATION AFTER COVID-19 VACCINATION A potential association between vaccination against COVID-19 and herpes zoster (HZ) reactivation in patients with stable autoimmune inflammatory rheumatic diseases (AIIRD) was examined, and the results of the report were published in Rheumatology.Study authors noted that among patients with AIIRD who received the Pfizer-BioNTech COVID-19 vaccine, the prevalence of herpes zoster was COVID-19 VACCINATION IN AUTOIMMUNE DISEASES: PATIENT This feature is part of the Autoimmune Disease Awareness Month series. The Centers for Disease Control and Prevention (CDC) recommends that individuals with autoimmune diseases and those with weakened immune systems receive the COVID-19 vaccines; however, no solid data are currently available regarding their safety specifically in populations with autoimmune conditions. 1 On COUNSELING IMMUNOCOMPROMISED PATIENTS ABOUT THE JOHNSONAUTHOR: MEGHNARAO
In February 2021, the American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Task Force developed recommendations for providers regarding the use of the COVID-19 vaccine and the management of patients with rheumatic and musculoskeletal diseases (RMDs) during vaccination. 1 This “living” document was updated in March 2021 to reflect evolving evidence and TREAT-TO-TARGET STRATEGY HELPS ELDERLY PATIENTS WITH In elderly patients with new-onset rheumatoid arthritis (RA), a treat-to-target (T2T) strategy using methotrexate (MTX) and biologic disease-modifying antirheumatic drugs (bDMARDs) was safe and effective, according to study results published in Rheumatology.. The recommended approach for treatment of patients with RA is based on levels of disease activity and additional patient factors. DO VACCINES INCREASE RISK FOR GOUT FLARES? Vaccines May Increase Risk for Gout Flares, But Benefits of Vaccination Outweigh Risks. Tom Greenhalgh. Patients with gout were found to be twice as likely to experience a flare in the days following vaccination compared with periods when vaccination was not administered. Patients with gout were found to be twice as likely toexperience a flare
RHEUMATOLOGY CASE STUDIES Rheumatology disorders case studies, news and clinical highlights about rheumatoid arthritis, sle, scleroderma and more. Download our app for updated case studies. CHARACTERISTICS OF PATIENTS WITH AXIAL PSA AND AXSPA 1 day ago · The following article is a part of conference coverage from the European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress, held online from June 2 to 5, 2021. The team at Rheumatology Advisor will be reporting on the latest news and GEOGRAPHIC AND TEMPORAL VARIATIONS OBSERVED WITH The use of repurposed and adjuvant drugs during the COVID-19 pandemic varied geographically and temporally, based on the emergence of safety and efficacy data, according to findings from a multinational cohort study published in BMJ.. The urgency during the COVID-19 pandemic led to the rapid use of repurposed drugs and adjunctive treatments, without evidence of their effectiveness. A CLOSER LOOK AT THE RISK FOR SEVERE OUTCOMES WITH LOW The risk for severe outcomes with low-dose glucocorticoids in patients with rheumatoid arthritis (RA) increases over time, particularly after 6 years and up to 10 years of treatment, study findings published in Rheumatology suggest.. This study analyzed 10-year outcomes data obtained from the prospective, observational ESPOIR cohort, which included patients with early arthritis (mean age, 47.5 PHASE 3 TRIAL SHOWS INTRAVENOUS IMMUNOGLOBULIN THERAPY 1 day ago · The following article is a part of conference coverage from the European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress, held online from June 2 to 5, 2021. The team at Rheumatology Advisor will be reporting on the latest news and FAVORABLE SAFETY AND EFFICACY PROFILE OF GUSELKUMAB IN The following article is a part of conference coverage from the European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress, held online from June 2 to 5, 2021.The team at Rheumatology Advisor will be reporting on the latest news and research conducted by leading experts in rheumatology. THE CHALLENGES OF MANAGING COMORBIDITIES IN RHEUMATOID Further increases occurred within the year of diagnosis (8.7 disorders), followed by a decline in the 5 years after diagnosis (6.9 disorders). The top comorbidities in patients with RA compared with control participants were musculoskeletal, hematologic, and neurologic disorders. 3 Results of a 2019 study coauthored by Vanessa L. Kronzer, MD, an internal medicine resident at Mayo Clinic in TNF INHIBITOR THERAPY IMPROVES BODY COMPOSITION, MUSCLE At 1 year after TNFi treatment, body composition changes corresponded with an improvement in handgrip strength and walk test at 6 months and 12 months. Credit: Getty Images Treatment with a tumor necrosis factor inhibitor (TNFi) for 1 year was associated with favorable changes intotal lean mass
10 FREE RHEUMATOLOGY CME COURSES 10 Free Rheumatology CME Courses. Check out our top 10 CME courses in rheumatology, focusing on conditions such as rheumatoid arthritis, psoriatic arthritis and gout. RHEUMATOLOGY ADVISOR Browse content from Rheumatology Advisor's numerous topics including osteoarthritis, pain management, psoriatic arthritis and more. RHEUMATOLOGY ADVISORRHEUMATOID ARTHRITISSPONDYLOARTHRITISOSTEOARTHRITISLUPUSGOUTNEWS Assistant professor in medicine and pediatrics and study author Rebecca Sadun, MD, discusses current health care transition practices and beliefs among CARRA rheumatology providers and provides insight into the positive impact of improvements to the transition process from pediatric to adult rheumatology care. ACR UPDATES COVID-19 VACCINE GUIDANCE FOR MANAGING In February 2021, the American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Task Force released a summary of consensus-based recommendations for the management of patients with rheumatic and musculoskeletal diseases (RMDs) with regard to COVID-19vaccination.
HERPES ZOSTER REACTIVATION AFTER COVID-19 VACCINATION A potential association between vaccination against COVID-19 and herpes zoster (HZ) reactivation in patients with stable autoimmune inflammatory rheumatic diseases (AIIRD) was examined, and the results of the report were published in Rheumatology.Study authors noted that among patients with AIIRD who received the Pfizer-BioNTech COVID-19 vaccine, the prevalence of herpes zoster was COVID-19 VACCINATION IN AUTOIMMUNE DISEASES: PATIENT This feature is part of the Autoimmune Disease Awareness Month series. The Centers for Disease Control and Prevention (CDC) recommends that individuals with autoimmune diseases and those with weakened immune systems receive the COVID-19 vaccines; however, no solid data are currently available regarding their safety specifically in populations with autoimmune conditions. 1 On COUNSELING IMMUNOCOMPROMISED PATIENTS ABOUT THE JOHNSONAUTHOR: MEGHNARAO
In February 2021, the American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Task Force developed recommendations for providers regarding the use of the COVID-19 vaccine and the management of patients with rheumatic and musculoskeletal diseases (RMDs) during vaccination. 1 This “living” document was updated in March 2021 to reflect evolving evidence and TREAT-TO-TARGET STRATEGY HELPS ELDERLY PATIENTS WITH In elderly patients with new-onset rheumatoid arthritis (RA), a treat-to-target (T2T) strategy using methotrexate (MTX) and biologic disease-modifying antirheumatic drugs (bDMARDs) was safe and effective, according to study results published in Rheumatology.. The recommended approach for treatment of patients with RA is based on levels of disease activity and additional patient factors. DO VACCINES INCREASE RISK FOR GOUT FLARES? Vaccines May Increase Risk for Gout Flares, But Benefits of Vaccination Outweigh Risks. Tom Greenhalgh. Patients with gout were found to be twice as likely to experience a flare in the days following vaccination compared with periods when vaccination was not administered. Patients with gout were found to be twice as likely toexperience a flare
3 CONDITIONS THAT LOOKS LIKE LYME DISEASE Borrelia miyamotoi (B miyamotoi) disease is an emerging infectious disease spread by deer ticks.First discovered by Japanese scientists in 1995, B miyamotoi disease can be found in all areas of the United States where Lyme disease is endemic. 1 The first human cases of B miyamotoi infection were found in Russia in 2011, when researchers identified 46 patients who had presented with the JUVENILE SPONDYLOARTHRITIS: CLASSIFICATION AND TREATMENT Juvenile spondyloarthritis (SpA) is a distinct form of childhood arthritis that is closely associated with the presence of human leucocyte antigen (HLA)-B27. 1 In certain parts of the world, SpA represents up to one-third of juvenile idiopathic arthritis (JIA) cases. In North America, cohort studies of people with JIA suggest a prevalence of 10% to 11% for enthesitis-related arthritis, 6% to EFFECTS OF STATIN USE ON PAIN OUTCOMES IN KNEE Rheumatology Advisor Contributing Writer. After 4 years, participants using statins did not demonstrate a lowered risk of worsening pain. Patients with osteoarthritis (OA) who have used statins for more than 5 years and those using atorvastatin may have a lower risk for knee pain, according to findings published in Arthritis Care & Research. RHEUMATOLOGY ADVISORRHEUMATOID ARTHRITISSPONDYLOARTHRITISOSTEOARTHRITISLUPUSGOUTNEWS Assistant professor in medicine and pediatrics and study author Rebecca Sadun, MD, discusses current health care transition practices and beliefs among CARRA rheumatology providers and provides insight into the positive impact of improvements to the transition process from pediatric to adult rheumatology care. ACR UPDATES COVID-19 VACCINE GUIDANCE FOR MANAGING In February 2021, the American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Task Force released a summary of consensus-based recommendations for the management of patients with rheumatic and musculoskeletal diseases (RMDs) with regard to COVID-19vaccination.
HERPES ZOSTER REACTIVATION AFTER COVID-19 VACCINATION A potential association between vaccination against COVID-19 and herpes zoster (HZ) reactivation in patients with stable autoimmune inflammatory rheumatic diseases (AIIRD) was examined, and the results of the report were published in Rheumatology.Study authors noted that among patients with AIIRD who received the Pfizer-BioNTech COVID-19 vaccine, the prevalence of herpes zoster was COVID-19 VACCINATION IN AUTOIMMUNE DISEASES: PATIENT This feature is part of the Autoimmune Disease Awareness Month series. The Centers for Disease Control and Prevention (CDC) recommends that individuals with autoimmune diseases and those with weakened immune systems receive the COVID-19 vaccines; however, no solid data are currently available regarding their safety specifically in populations with autoimmune conditions. 1 On COUNSELING IMMUNOCOMPROMISED PATIENTS ABOUT THE JOHNSONAUTHOR: MEGHNARAO
In February 2021, the American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Task Force developed recommendations for providers regarding the use of the COVID-19 vaccine and the management of patients with rheumatic and musculoskeletal diseases (RMDs) during vaccination. 1 This “living” document was updated in March 2021 to reflect evolving evidence and TREAT-TO-TARGET STRATEGY HELPS ELDERLY PATIENTS WITH In elderly patients with new-onset rheumatoid arthritis (RA), a treat-to-target (T2T) strategy using methotrexate (MTX) and biologic disease-modifying antirheumatic drugs (bDMARDs) was safe and effective, according to study results published in Rheumatology.. The recommended approach for treatment of patients with RA is based on levels of disease activity and additional patient factors. DO VACCINES INCREASE RISK FOR GOUT FLARES? Vaccines May Increase Risk for Gout Flares, But Benefits of Vaccination Outweigh Risks. Tom Greenhalgh. Patients with gout were found to be twice as likely to experience a flare in the days following vaccination compared with periods when vaccination was not administered. Patients with gout were found to be twice as likely toexperience a flare
3 CONDITIONS THAT LOOKS LIKE LYME DISEASE Borrelia miyamotoi (B miyamotoi) disease is an emerging infectious disease spread by deer ticks.First discovered by Japanese scientists in 1995, B miyamotoi disease can be found in all areas of the United States where Lyme disease is endemic. 1 The first human cases of B miyamotoi infection were found in Russia in 2011, when researchers identified 46 patients who had presented with the JUVENILE SPONDYLOARTHRITIS: CLASSIFICATION AND TREATMENT Juvenile spondyloarthritis (SpA) is a distinct form of childhood arthritis that is closely associated with the presence of human leucocyte antigen (HLA)-B27. 1 In certain parts of the world, SpA represents up to one-third of juvenile idiopathic arthritis (JIA) cases. In North America, cohort studies of people with JIA suggest a prevalence of 10% to 11% for enthesitis-related arthritis, 6% to EFFECTS OF STATIN USE ON PAIN OUTCOMES IN KNEE Rheumatology Advisor Contributing Writer. After 4 years, participants using statins did not demonstrate a lowered risk of worsening pain. Patients with osteoarthritis (OA) who have used statins for more than 5 years and those using atorvastatin may have a lower risk for knee pain, according to findings published in Arthritis Care & Research. RHEUMATOLOGY CASE STUDIES Rheumatology disorders case studies, news and clinical highlights about rheumatoid arthritis, sle, scleroderma and more. Download our app for updated case studies. CHARACTERISTICS OF PATIENTS WITH AXIAL PSA AND AXSPA 22 hours ago · The following article is a part of conference coverage from the European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress, held online from June 2 to 5, 2021. The team at Rheumatology Advisor will be reporting on the latest news and GEOGRAPHIC AND TEMPORAL VARIATIONS OBSERVED WITH The use of repurposed and adjuvant drugs during the COVID-19 pandemic varied geographically and temporally, based on the emergence of safety and efficacy data, according to findings from a multinational cohort study published in BMJ.. The urgency during the COVID-19 pandemic led to the rapid use of repurposed drugs and adjunctive treatments, without evidence of their effectiveness. A CLOSER LOOK AT THE RISK FOR SEVERE OUTCOMES WITH LOW The risk for severe outcomes with low-dose glucocorticoids in patients with rheumatoid arthritis (RA) increases over time, particularly after 6 years and up to 10 years of treatment, study findings published in Rheumatology suggest.. This study analyzed 10-year outcomes data obtained from the prospective, observational ESPOIR cohort, which included patients with early arthritis (mean age, 47.5 PHASE 3 TRIAL SHOWS INTRAVENOUS IMMUNOGLOBULIN THERAPY 22 hours ago · The following article is a part of conference coverage from the European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress, held online from June 2 to 5, 2021. The team at Rheumatology Advisor will be reporting on the latest news and FAVORABLE SAFETY AND EFFICACY PROFILE OF GUSELKUMAB IN 1 day ago · The following article is a part of conference coverage from the European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress, held online from June 2 to 5, 2021.The team at Rheumatology Advisor will be reporting on the latest news and research conducted by leading experts in rheumatology. THE CHALLENGES OF MANAGING COMORBIDITIES IN RHEUMATOID Further increases occurred within the year of diagnosis (8.7 disorders), followed by a decline in the 5 years after diagnosis (6.9 disorders). The top comorbidities in patients with RA compared with control participants were musculoskeletal, hematologic, and neurologic disorders. 3 Results of a 2019 study coauthored by Vanessa L. Kronzer, MD, an internal medicine resident at Mayo Clinic in TNF INHIBITOR THERAPY IMPROVES BODY COMPOSITION, MUSCLE At 1 year after TNFi treatment, body composition changes corresponded with an improvement in handgrip strength and walk test at 6 months and 12 months. Credit: Getty Images Treatment with a tumor necrosis factor inhibitor (TNFi) for 1 year was associated with favorable changes intotal lean mass
10 FREE RHEUMATOLOGY CME COURSES 10 Free Rheumatology CME Courses. Check out our top 10 CME courses in rheumatology, focusing on conditions such as rheumatoid arthritis, psoriatic arthritis and gout. RHEUMATOLOGY ADVISOR Browse content from Rheumatology Advisor's numerous topics including osteoarthritis, pain management, psoriatic arthritis and more. RHEUMATOLOGY ADVISORRHEUMATOID ARTHRITISSPONDYLOARTHRITISOSTEOARTHRITISLUPUSGOUTNEWS Assistant professor in medicine and pediatrics and study author Rebecca Sadun, MD, discusses current health care transition practices and beliefs among CARRA rheumatology providers and provides insight into the positive impact of improvements to the transition process from pediatric to adult rheumatology care. ACR UPDATES COVID-19 VACCINE GUIDANCE FOR MANAGING In February 2021, the American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Task Force released a summary of consensus-based recommendations for the management of patients with rheumatic and musculoskeletal diseases (RMDs) with regard to COVID-19vaccination.
HERPES ZOSTER REACTIVATION AFTER COVID-19 VACCINATION A potential association between vaccination against COVID-19 and herpes zoster (HZ) reactivation in patients with stable autoimmune inflammatory rheumatic diseases (AIIRD) was examined, and the results of the report were published in Rheumatology.Study authors noted that among patients with AIIRD who received the Pfizer-BioNTech COVID-19 vaccine, the prevalence of herpes zoster was COVID-19 VACCINATION IN AUTOIMMUNE DISEASES: PATIENT This feature is part of the Autoimmune Disease Awareness Month series. The Centers for Disease Control and Prevention (CDC) recommends that individuals with autoimmune diseases and those with weakened immune systems receive the COVID-19 vaccines; however, no solid data are currently available regarding their safety specifically in populations with autoimmune conditions. 1 On COUNSELING IMMUNOCOMPROMISED PATIENTS ABOUT THE JOHNSONAUTHOR: MEGHNARAO
In February 2021, the American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Task Force developed recommendations for providers regarding the use of the COVID-19 vaccine and the management of patients with rheumatic and musculoskeletal diseases (RMDs) during vaccination. 1 This “living” document was updated in March 2021 to reflect evolving evidence andTHYROID SYNDROMES
Does this patient have thyroid syndrome? Thyroid disease can be accompanied by a variety of musculoskeletal manifestations ranging from early growth defects during infancy to adult manifestations including myalgias, arthralgias, myopathy, acropachy and frank arthritis. Musculoskeletal manifestations are most pronounced in extreme states of thyroid dysfunction. A thorough history is essential DO VACCINES INCREASE RISK FOR GOUT FLARES? Vaccines May Increase Risk for Gout Flares, But Benefits of Vaccination Outweigh Risks. Tom Greenhalgh. Patients with gout were found to be twice as likely to experience a flare in the days following vaccination compared with periods when vaccination was not administered. Patients with gout were found to be twice as likely toexperience a flare
SWALLOWING DISORDERS IN RA: EPIDEMIOLOGY AND PATIENT Among the range of symptoms that may affect patients with rheumatoid arthritis (RA), oral, pharyngeal, and esophageal motility disorders are common. The estimated prevalence of swallowing dysfunction in this patient population is 13.1% to 33.3%. 1,2 Oropharyngeal dysphagia caused by xerostomia, masticatory impairment, and cricoarytenoid joint dysfunction has been reported. 3 In 3 CONDITIONS THAT LOOKS LIKE LYME DISEASE Borrelia miyamotoi (B miyamotoi) disease is an emerging infectious disease spread by deer ticks.First discovered by Japanese scientists in 1995, B miyamotoi disease can be found in all areas of the United States where Lyme disease is endemic. 1 The first human cases of B miyamotoi infection were found in Russia in 2011, when researchers identified 46 patients who had presented with the EFFECTS OF STATIN USE ON PAIN OUTCOMES IN KNEE Rheumatology Advisor Contributing Writer. After 4 years, participants using statins did not demonstrate a lowered risk of worsening pain. Patients with osteoarthritis (OA) who have used statins for more than 5 years and those using atorvastatin may have a lower risk for knee pain, according to findings published in Arthritis Care & Research. RHEUMATOLOGY ADVISORRHEUMATOID ARTHRITISSPONDYLOARTHRITISOSTEOARTHRITISLUPUSGOUTNEWS Assistant professor in medicine and pediatrics and study author Rebecca Sadun, MD, discusses current health care transition practices and beliefs among CARRA rheumatology providers and provides insight into the positive impact of improvements to the transition process from pediatric to adult rheumatology care. ACR UPDATES COVID-19 VACCINE GUIDANCE FOR MANAGING In February 2021, the American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Task Force released a summary of consensus-based recommendations for the management of patients with rheumatic and musculoskeletal diseases (RMDs) with regard to COVID-19vaccination.
HERPES ZOSTER REACTIVATION AFTER COVID-19 VACCINATION A potential association between vaccination against COVID-19 and herpes zoster (HZ) reactivation in patients with stable autoimmune inflammatory rheumatic diseases (AIIRD) was examined, and the results of the report were published in Rheumatology.Study authors noted that among patients with AIIRD who received the Pfizer-BioNTech COVID-19 vaccine, the prevalence of herpes zoster was COVID-19 VACCINATION IN AUTOIMMUNE DISEASES: PATIENT This feature is part of the Autoimmune Disease Awareness Month series. The Centers for Disease Control and Prevention (CDC) recommends that individuals with autoimmune diseases and those with weakened immune systems receive the COVID-19 vaccines; however, no solid data are currently available regarding their safety specifically in populations with autoimmune conditions. 1 On COUNSELING IMMUNOCOMPROMISED PATIENTS ABOUT THE JOHNSONAUTHOR: MEGHNARAO
In February 2021, the American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Task Force developed recommendations for providers regarding the use of the COVID-19 vaccine and the management of patients with rheumatic and musculoskeletal diseases (RMDs) during vaccination. 1 This “living” document was updated in March 2021 to reflect evolving evidence andTHYROID SYNDROMES
Does this patient have thyroid syndrome? Thyroid disease can be accompanied by a variety of musculoskeletal manifestations ranging from early growth defects during infancy to adult manifestations including myalgias, arthralgias, myopathy, acropachy and frank arthritis. Musculoskeletal manifestations are most pronounced in extreme states of thyroid dysfunction. A thorough history is essential DO VACCINES INCREASE RISK FOR GOUT FLARES? Vaccines May Increase Risk for Gout Flares, But Benefits of Vaccination Outweigh Risks. Tom Greenhalgh. Patients with gout were found to be twice as likely to experience a flare in the days following vaccination compared with periods when vaccination was not administered. Patients with gout were found to be twice as likely toexperience a flare
SWALLOWING DISORDERS IN RA: EPIDEMIOLOGY AND PATIENT Among the range of symptoms that may affect patients with rheumatoid arthritis (RA), oral, pharyngeal, and esophageal motility disorders are common. The estimated prevalence of swallowing dysfunction in this patient population is 13.1% to 33.3%. 1,2 Oropharyngeal dysphagia caused by xerostomia, masticatory impairment, and cricoarytenoid joint dysfunction has been reported. 3 In 3 CONDITIONS THAT LOOKS LIKE LYME DISEASE Borrelia miyamotoi (B miyamotoi) disease is an emerging infectious disease spread by deer ticks.First discovered by Japanese scientists in 1995, B miyamotoi disease can be found in all areas of the United States where Lyme disease is endemic. 1 The first human cases of B miyamotoi infection were found in Russia in 2011, when researchers identified 46 patients who had presented with the EFFECTS OF STATIN USE ON PAIN OUTCOMES IN KNEE Rheumatology Advisor Contributing Writer. After 4 years, participants using statins did not demonstrate a lowered risk of worsening pain. Patients with osteoarthritis (OA) who have used statins for more than 5 years and those using atorvastatin may have a lower risk for knee pain, according to findings published in Arthritis Care & Research. COVID-19 AND INCIDENT SYSTEMIC RHEUMATIC DISEASE Study authors determined the potential association between COVID-19 and subsequent diagnosis with a systemic rheumatic disease, in a correspondence paper published in Lancet Rheumatology.Using a case series study, the authors noted that a small number of patients developed incident rheumatic disease following infection with SARS-CoV-2, suggesting that COVID-19 may CHARACTERISTICS OF PATIENTS WITH AXIAL PSA AND AXSPA 2 hours ago · The following article is a part of conference coverage from the European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress, held online from June 2 to 5, 2021. The team at Rheumatology Advisor will be reporting on the latest news and RHEUMATOLOGY CASE STUDIES Rheumatology disorders case studies, news and clinical highlights about rheumatoid arthritis, sle, scleroderma and more. Download our app for updated case studies. GEOGRAPHIC AND TEMPORAL VARIATIONS OBSERVED WITH The use of repurposed and adjuvant drugs during the COVID-19 pandemic varied geographically and temporally, based on the emergence of safety and efficacy data, according to findings from a multinational cohort study published in BMJ.. The urgency during the COVID-19 pandemic led to the rapid use of repurposed drugs and adjunctive treatments, without evidence of their effectiveness. A CLOSER LOOK AT THE RISK FOR SEVERE OUTCOMES WITH LOW 1 day ago · The risk for severe outcomes with low-dose glucocorticoids in patients with rheumatoid arthritis (RA) increases over time, particularly after 6 years and up to 10 years of treatment, study findings published in Rheumatology suggest.. This study analyzed 10-year outcomes data obtained from the prospective, observational ESPOIR cohort, which included patients with early arthritis (mean age,47.5
PHASE 3 TRIAL SHOWS INTRAVENOUS IMMUNOGLOBULIN THERAPY 2 hours ago · The following article is a part of conference coverage from the European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress, held online from June 2 to 5, 2021. The team at Rheumatology Advisor will be reporting on the latest news and THE CHALLENGES OF MANAGING COMORBIDITIES IN RHEUMATOID 1 day ago · Further increases occurred within the year of diagnosis (8.7 disorders), followed by a decline in the 5 years after diagnosis (6.9 disorders). The top comorbidities in patients with RA compared with control participants were musculoskeletal, hematologic, and neurologic disorders. 3 Results of a 2019 study coauthored by Vanessa L. Kronzer, MD, an internal medicine resident at Mayo Clinic in PHASE 3 STUDY RESULTS INDICATE TOFACITINIB IS SAFE AND Tofacitinib demonstrated greater efficacy compared with placebo in patients with active ankylosing spondylitis (AS) with an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs), according to phase 3 study results published in Annals of the Rheumatic Diseases.. For AS, NSAIDs are the first-line treatment, followed by biologic disease-modifying antirheumatic drugsTHYROID SYNDROMES
Does this patient have thyroid syndrome? Thyroid disease can be accompanied by a variety of musculoskeletal manifestations ranging from early growth defects during infancy to adult manifestations including myalgias, arthralgias, myopathy, acropachy and frank arthritis. Musculoskeletal manifestations are most pronounced in extreme states of thyroid dysfunction. A thorough history is essential RHEUMATOLOGY ADVISOR Browse content from Rheumatology Advisor's numerous topics including osteoarthritis, pain management, psoriatic arthritis and more. Skip to navigation Skip to main content Menu Close Search... Submit * Rheumatoid Arthritis* Spondyloarthritis
Open
Submenu
* Spondyloarthritis
Back
* Ankylosing Spondylitis * Psoriatic Arthritis* Osteoarthritis
* Lupus
* Gout
* More Open Submenu
* More Back
* Connective Tissue Disease* Fibromyalgia
* Lyme Disease
* Osteoporosis
* Pain Management
* Practice Management* Vasculitis
* Scleroderma
* Inflammatory Myopathy * Pediatric Rheumatology * General RheumatologyToggle Search Menu
* News
* Features
* CME
* Drugs
* Charts
* Media
* Resources
* Calculators
* Jobs
* Meetings
Login Register
*
*
LATEST NEWS
FLU VACCINES ARE STRONGLY RECOMMENDED FOR PATIENTS WITH RHEUMATICDISEASES
PATIENTS WITH SCLERODERMA REPORT HEALTH-RELATED BARRIERS TO PHYSICALACTIVITY
ANTIRHEUMATIC THERAPY DECREASES OPIOID USE IN PATIENTS WITH EARLY INFLAMMATORY ARTHRITIDES CHANGES ASSOCIATED WITH COVID-19 REPORTED IN RHEUMATIC DISEASEPATIENT CARE
GOLIMUMAB SBLAS FOR JIA, JUVENILE PSORIATIC ARTHRITIS SUBMITTED FORFDA REVIEW
HYDROXYCHLOROQUINE TREATMENT MAY NOT REDUCE VENTILATOR USE INCOVID-19
VISUAL FUNCTIONS IN PSORIATIC ARTHRITIS SINE-PSORIASIS MAY BE LINKED TO SYSTEMIC INFLAMMATION FDA GREENLIGHTS NOVARTIS TRIAL INVESTIGATING HYDROXYCHLOROQUINE FORCOVID-19
DULOXETINE APPROVED FOR PEDIATRIC PATIENTS WITH FIBROMYALGIA FIBROMYALGIA AND WIDESPREAD PAIN WEAKLY ASSOCIATED WITH MORTALITY OVERWEIGHT OR OBESE BMI IN PRESCHOOLERS ASSOCIATED WITH INCREASEDFRACTURE RISK
TELITACICEPT FAST-TRACKED FOR THE TREATMENT OF SYSTEMIC LUPUSERYTHEMATOSUS
more news >>
LATEST FEATURES
WHAT RHEUMATOLOGISTS NEED TO KNOW ABOUT VACCINES IN RHEUMATICDISEASES
What are the top 3 things that rheumatologists need to know about vaccines in rheumatic diseases? UPDATED EULAR/ERA-EDTA RECOMMENDATIONS FOR THE MANAGEMENT OF LUPUSNEPHRITIS
The EULAR/ERA-EDTA developed updated recommendations for the management of lupus nephritis. WORKING REMOTELY DURING THE COVID-19 PANDEMIC The US Department of Health and Human Services has given healthcare providers more latitude in delivering care via telemedicine. ACR DEVELOPS CLINICAL GUIDANCE FOR THE MANAGEMENT OF RHEUMATIC DISEASES DURING THE COVID-19 PANDEMIC The American College of Rheumatology developed clinical guidance for rheumatology providers for the management of rheumatic diseases during the COVID-19 pandemic.more features >>
-------------------------OPINIONS
General Rheumatology ADJUSTING APPROACHES TO PATIENT CARE IN RHEUMATOLOGY DURING THECOVID-19 PANDEMIC
John K Botson, MD, discusses how clinicians in the rheumatology space can adjust their approach to patient care during the COVID-19pandemic.
Rheumatoid Arthritis SEIZING THE OPPORTUNITY TO CREATE CHANGE IN THE RHEUMATOLOGY FIELD Effective and affordable treatment options are essential to controlling costs within the rheumatoid arthritis treatment space and delivering value to patients.Pain Management
THE OPIOID EPIDEMIC: WHY YOUR PRESCRIBING HABITS MATTER If physicians have a genuine interest in acting with beneficence and nonmaleficence, they should recognize that their prescribing habits have significant consequences for their patients.Practice Management
REEXAMINING THE ROLE OF CONCIERGE MEDICINE IN PRIMARY CARE During the last decade, the number of medical students choosing internal or family medicine has dropped by approximately 80%.Opinion
WEARABLE FITNESS TRACKERS: ARE WE PLACING TOO MUCH FAITH IN THEM? The utility and effectiveness of wearable fitness devices are discussed in a clinician’s opinion piece.more >>
-------------------------CASE STUDIES
CASE STUDY: SYSTEMIC LUPUS ERYTHEMATOSUS WITH LUPUS NEPHRITIS AND THROMBOTIC MICROANGIOPATHYBy
Yongen Chang, MD, PhD, and Eric Seronick, DO A 19-year-old woman presents with complaints of progressive shortness of breath, chest pain, and lower extremity edema over the past month. CASE STUDY: A SYNCOPAL EPISODE DURING A CAMPING TRIPBy
George Marzouka, MD
A 52-year-old man presents to the emergency department with dizziness and fatigue after a syncopal episode on a camping trip. CASE STUDY: RHEUMATOID ARTHRITIS CARDIAC MANIFESTATIONSBy
George Marzouka, MD
A 69 year old man presents joint pain (wrists, elbows, hands, and knees) and swelling with no evidence of erosions. CASE STUDY AND CLINICAL HIGHLIGHT: RESPIRATORY FAILURE IN A PATIENTWITH SLE
By
Corinna Sison, MD
A female patient with systemic lupus erythematosus presents to the emergency department with an 8 week history of dyspnea, dysphonia, and non-productive cough. CASE STUDY AND CLINICAL HIGHLIGHT: A PATIENT WITH NEPHROTIC SYNDROME AND ANKYLOSING SPONDYLITISBy
Corinna Sison, MD
AA amyloidosis is a rare but significant complication of ankylosing spondylitis (AS) and may lead to proteinuria and renal dysfunction.more >>
-------------------------SLIDESHOWS
UNCOMMON MIMICKERS OF SYSTEMIC LUPUS ERYTHEMATOSUS SKELETAL COMPLICATIONS IN RHEUMATOID ARTHRITIS: A COMPREHENSIVEREVIEW
PREDICTIONS IN MEDICINE 2019: WHAT’S AHEAD DERM DX: ERYTHEMATOUS RASH ON THE UPPER BACK [Ischemic stroke is the most common severe neurologic complication of APS. Among 1000 people with APS participating in the Euro-Phospholipid Project, 20% presented with stroke and 11% presented with transient ischemic stroke.2,5 About 13% of patients with stroke are aPL-positive,2 and they are more likely to be younger or female compared with aPL-negative patients.3 More than 20% of strokes inpatients
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0